Section Arrow
IRD.NASDAQ
- Opus Genetics Inc
Quotes are at least 15-min delayed:2024/12/23 22:16 EST
Last
 1.03
+0.0515 (+5.26%)
Day High 
1.05 
Prev. Close
0.9785 
1-M High
1.22 
Volume 
152.47K 
Bid
1.03
Ask
1.04
Day Low
0.9525 
Open
1-M Low
0.81 
Market Cap 
30.89M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.04 
20-SMA 1.08 
50-SMA 1.13 
52-W High 3.31 
52-W Low 0.81 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.09/-0.82
Enterprise Value
30.89M
Balance Sheet
Book Value Per Share
1.09
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
19.05M
Operating Revenue Per Share
1.73
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.4031-0.2085-34.09%-- 
RAPTRAPT Therapeutics1.74+0.9146+110.81%-- 
TRAWTraws Pharma Inc12.57+7.55+150.40%-- 
CEROCERo Therapeutics Holdings0.0505-0.0056-9.98%-- 
RXRXRecursion Pharmaceuticals6.99+0.96+15.92%-- 
Quotes are at least 15-min delayed:2024/12/23 22:16 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.